



This is a repository copy of *TRICALS: creating a highway toward a cure*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/163656/>

Version: Published Version

Article:

van Eijk, R.P.A., Kliest, T., McDermott, C.J. orcid.org/0000-0002-1269-9053 et al. (12 more authors) (2020) TRICALS: creating a highway toward a cure. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, 21 (7-8). pp. 496-501. ISSN 2167-8421

<https://doi.org/10.1080/21678421.2020.1788092>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

ISSN: (Print) (Online) Journal homepage: <https://www.tandfonline.com/loi/iafd20>

TRICALS: creating a highway toward a cure

Ruben P.A. van Eijk , Tessa Kliest , Christopher J. McDermott , Kit C.B. Roes , Philip Van Damme , Adriano Chio , Markus Weber , Caroline Ingre , Philippe Corcia , Mònica Povedano , Evy Reviers , Michael A. van Es , Ammar Al-Chalabi , Orla Hardiman & Leonard H. van den Berg

To cite this article: Ruben P.A. van Eijk , Tessa Kliest , Christopher J. McDermott , Kit C.B. Roes , Philip Van Damme , Adriano Chio , Markus Weber , Caroline Ingre , Philippe Corcia , Mònica Povedano , Evy Reviers , Michael A. van Es , Ammar Al-Chalabi , Orla Hardiman & Leonard H. van den Berg (2020): TRICALS: creating a highway toward a cure, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, DOI: [10.1080/21678421.2020.1788092](https://doi.org/10.1080/21678421.2020.1788092)

To link to this article: <https://doi.org/10.1080/21678421.2020.1788092>



© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group



Published online: 09 Jul 2020.



Submit your article to this journal



Article views: 577



View related articles



View Crossmark data

REVIEW ARTICLE

TRICALS: creating a highway toward a cure

RUBEN P.A. VAN EIJK^{*1,2}, TESSA KLIEST^{*1}, CHRISTOPHER J. MCDERMOTT³ , KIT C.B. ROES⁴, PHILIP VAN DAMME^{5,6} , ADRIANO CHIO^{7,8} , MARKUS WEBER⁹, CAROLINE INGRE^{10,11}, PHILIPPE CORCIA¹², MÒNICA POVEDANO¹³, EVY REVIVERS¹⁴, MICHAEL A. VAN ES¹, AMMAR AL-CHALABI^{15,16} , ORLA HARDIMAN^{17,18*} & LEONARD H. VAN DEN BERG^{1*}

¹Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands, ²Biostatistics & Research Support, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands, ³Department of Neuroscience, University of Sheffield, Sheffield Institute for Translational Neuroscience, Sheffield, UK, ⁴Department of Health Evidence, Section Biostatistics, Radboud Medical Centre Nijmegen, the Netherlands, ⁵Department of Neurosciences, Laboratory for Neurobiology, KU Leuven and Center for Brain & Disease Research, VIB, Leuven Brain Institute, Leuven, Belgium, ⁶Department of Neurology, University Hospital Leuven, Leuven, Belgium, ⁷Rita Levi Montalcini' Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy, ⁸Azienda Ospedaliera Città della Salute e della Scienza, Turin, Italy, ⁹Neuromuscular Disease Unit/ALS Clinic, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ¹⁰Department of Neurology, Karolinska University Hospital, Stockholm, Sweden, ¹¹Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ¹²Centre Constitutif SLA, CHRU de Tours - Fédération des centres SLA Tours-Limoges, LitORALS, Tours, France, ¹³Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, Hospitalet de Llobregat, Spain, ¹⁴European Organization for Professionals and Patients with ALS (EUpALS), Leuven, Belgium, ¹⁵Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute and United Kingdom Dementia Research Institute Centre, King's College London, London, UK, ¹⁶Department of Neurology, King's College Hospital, London, UK, ¹⁷Department of Neurology, National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland, and ¹⁸FutureNeuro SFI Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland

Abstract

A change in our current approach toward drug development is required to improve the likelihood of finding effective treatment for patients with amyotrophic lateral sclerosis (ALS). The aim of the Treatment Research Initiative to Cure ALS (TRICALS) is to extend the collective effort with industry and consolidate drug development paths. TRICALS has begun a series of meetings on how to best move the field forward collaboratively, thereby addressing five major topics in ALS clinical trials: (1) preclinical research, (2) biomarker development, (3) eligibility criteria, (4) efficacy endpoints and (5) innovative trial design. There is an appetite for ongoing discussions of these major topics in clinical trials between representatives from academia, patient advocacy groups, industry partners and funding bodies. Industry is open to fundamentally change drug development for ALS and shorten the time to effective therapy for patients by implementing promising innovations in biomarker development, trial design, and patient selection. There is however, a pressing need from all stakeholders for regulatory discussions and amendments of current guidelines to successfully adopt innovation in future clinical development lines.

Keywords: Clinical trial design, biomarkers, preclinical, guidelines

Correspondence: Leonard H. van den Berg, Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands. Tel: +31 (0) 88 75 554 94. Fax: +31 (0) 88 75 554 94. Email: lberg@umcutrecht.nl

*These authors contributed equally.

(Received 17 April 2020; revised 17 June 2020; Accepted 21 June 2020)

ISSN 2167-8421 print/ISSN 2167-9223 online © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

DOI: 10.1080/21678421.2020.1788092

Introduction

It has been nearly 25 years since the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) approved riluzole (1). Recently, edaravone was approved by the FDA for delaying motor function deterioration (2). A benefit to life expectancy remains, however, to be determined and riluzole remains the only available treatment for European patients with amyotrophic lateral sclerosis (ALS). Over 70 compounds have been tested (3), but despite considerable efforts from industry and academia, and promising early signals, none of the treatments has been effective in slowing the course of the illness or prolonging survival. The reasons for this failure in translation from animal models to human trials are multifactorial, but can be grouped into five major categories—namely: (1) disease heterogeneity and our relatively limited knowledge of the interplay between different disease mechanisms in humans; (2) inappropriate use of pre-clinical experimental models of mechanisms and not disease; (3) an absence of biomarkers of pathogenic mechanisms, markers of disease onset, and quantitative markers of progression; (4) pharmacological challenges of dosing and measures of target engagement and (5) inefficient or poorly designed clinical trials (4–6).

There is now an urgent need to rethink the clinical development pathway for ALS treatments. This will require large-scale collaboration between various stakeholders and important adjustments to our current approaches. Hence, we established the Treatment Research Initiative to Cure ALS (TRICALS) to (1) unify academia, patient advocacy groups, industry partners and funding bodies toward a common goal in finding a cure for patients, (2) provide a harmonized, international infrastructure for the conduct of clinical trials and (3) coordinate research efforts that maximize the likelihood of successful drug development.

Currently, the TRICALS consortium consists of 40 specialized centers in 14 countries, diagnosing over 3800 patients with ALS each year. TRICALS has begun a series of meetings with industry partners to discuss how best to move the field forward collaboratively, such that the best drugs are fast-tracked to the clinic using new and appropriately designed strategies that are both scientifically robust and compliant with the requirements of regulatory authorities. Five main topics are currently being explored within this collaborative effort and are discussed below.

Preclinical and translational research

Background

Prior to clinical use, safety and target engagement of new therapeutics need to be established in

experimental models. Despite its well-documented drawbacks, the superoxide dismutase 1 (*SOD1*) transgenic model remains the gold standard to obtain preclinical insights into disease-modifying properties. Although preclinical studies with *SOD1* models can in part replicate mutant *SOD1* familial ALS, the pathophysiological processes do not seem to recapitulate the mechanisms underlying sporadic disease and animals are often treated prior to disease onset (4,7). In addition, even if a clear pathway is being examined, either in familial or sporadic ALS, there is often a lack of translational markers of target engagement. As a result, preclinical studies may falsely trigger the continuation of drugs to clinical phases.

Considerations

Optimizing preclinical study design may significantly improve the utility and predictive value of *SOD1* and other disease models for subsequent clinical trials (8). Moreover, given the rise of anti-sense oligonucleotide therapies (9), specific pre-clinical models based on a genetic mutation are likely to prove useful to evaluate preliminary drug safety profiles and pharmacodynamics (7,10). Moreover, if there is a clear pathophysiological pathway, the *SOD1* model may still serve as feasible preclinical model as long as adequate biomarkers of target engagement are being incorporated (10). It is, therefore, important to develop not only new preclinical models, but also to simultaneously advance biomarkers of target engagement. Intermediate translational steps will be required to validate and replicate these new markers of target engagement in both preclinical as clinical studies. Examples include the use of neurophysiological biomarkers in phase 1 studies (11) or misfolded *SOD1* protein levels.

Future directions

There is an acknowledged need for (1) additional models that better capture the heterogeneity of the disease and (2) markers of target engagement to improve preclinical to clinical translation. In vivo preclinical models can generate valuable insight in blood-brain-barrier permeability and, especially for small molecules, it will be critical that the relevant pharmacokinetic studies are included. Furthermore, human derived stem cell models hold promise in the determination of disease mechanisms, opening the possibility for high-throughput screening tools and personalized medicine (12).

Biomarkers

Background

Biomarkers can enhance patient selection, improve prognostication, evaluate and predict biological treatment response or serve as surrogate outcome (4,13,14). Notwithstanding, the majority of clinical trials may not optimally use biomarkers, thereby potentially missing responding subgroups, lacking the ability to quantify target engagement or subtle treatment effects, and not gain knowledge on biomarkers of the disease (4,14).

Considerations

The multicentre setting of clinical trials provide an ideal environment to evaluate the association between a biomarker and classical clinical endpoints, and to determine its reliability, test-retest validity and site variability (15). Biomarkers should be defined as to their potential utility in all phases of clinical development (e.g. markers of specific pathogenic processes; markers of specific subgroups; markers of target engagement; markers of disease progression etc) (4,5). Examples of markers that are “clinical trial ready” include neurofilaments. Neurofilaments have been shown to be stable over time and may be helpful to stratify patients and quantify treatment response (16,17). Other easily accessible biomarkers such as creatinine, inflammatory markers or urinary P75^{ECD} are of potential utility and could be considered as exploratory or secondary endpoints (14,16,18).

Future directions

Neurofilaments have the potential to improve multiple aspects of ALS clinical trials and should be implemented at all stages of drug development. Other markers that could be of utility include biochemical, transcriptomic and proteomic measures, neuroimaging (including PET) and advanced neurophysiology including neuroelectric signal analysis. Combinations of different biomarkers are likely to provide additional benefit and should therefore be part of any clinical development program. Open-access initiatives and prospective data collection are vital for their validation. Ultimately, associating treatment responses on biomarkers with those on classical clinical endpoints could prove their surrogate value and thereby improve trial efficiency (19). It is thereby essential that the same biomarkers are used in all clinical trials to evaluate their surrogate value across a range of different treatment effects (20).

Eligibility criteria

Background

Eligibility criteria are the primary tool to manage population heterogeneity and increase the probability of detecting effective compounds. Classically defined eligibility criteria (e.g. fixed boundaries for symptom duration, vital capacity or diagnostic delay) are inefficient and of limited value (21,22). Inefficiencies can be attributed to the mathematical processes that are used to exclude cohorts of patients whose pattern of progression is either too fast or too slow. A univariate, step-wise application is inconsistent with the pattern of human disease, which is best defined by a multivariate combination of several characteristics (23). Using classical eligibility criteria, large numbers of patients are excluded while conferring minimal gains in population homogeneity and severely limiting the generalizability of results.

Considerations

Current eligibility criteria should, therefore, be revised. This would have the dual benefits of increasing eligibility rates and improving population homogeneity. Simple multivariate prediction rules could be defined for individual patients that optimize the use of prognostic information and improve patient selection (22). Such an approach would bypass the need for group-level univariate selection rules. Indeed, several validated prediction rules are already available for different primary outcomes (e.g. the ENCALS and Origent model for survival and functional outcomes, respectively) (23,24).

Future directions

Prediction of unfavorable disease patterns is of particular interest for industry in order to increase trial efficiency. However, prediction-based eligibility criteria are currently not part of trial guidelines and regulatory discussions are required for successful implementation in future settings.

Efficacy endpoints and follow-up duration

Background

Efficacy endpoints must be clinically meaningful, sensitive to change and reliable in test-retest settings (5,25). Composite survival endpoints and the revised ALS Functional Rating Scale (ALSFRS-R) are currently the primary measures of efficacy in ALS clinical trials (26). Nevertheless, up to now, early phase 2 trial outcomes that are based on the slope of the ALSFRS-R have translated poorly to confirmatory trials evaluating mortality (13).

Considerations

In order to improve the translational power of exploratory to confirmatory trials, the follow-up duration of exploratory trials should be increased to at least 6 months and indicate a response in biomarkers of target engagement, or in multiple clinical endpoints, prior to initiation of a confirmatory trial. As showing a therapeutic benefit on mortality is required by European regulators for market authorization (25), the follow-up duration of confirmatory trials should be increased to at least 12 months in order to design trials with feasible sample sizes (27). Halting or slowing motor neuron degeneration may be slow, and take time to manifest in trial endpoints. The power to quantify a survival benefit can be improved by employing the Joint Modeling Framework (14). In addition, remote digital technology can help to further define the real-world functional benefits of a therapeutic intervention (13,27,28), whereas extensive training on outcome measures as organized by TRICALS and Northeast ALS Consortium (NEALS) may warrant quality control and minimize endpoint variability (5,15).

Future directions

There is an urgent need to better translate exploratory clinical trials to confirmatory settings, which requires innovation of the current clinical endpoints. The ALSFRS-R has significant limitations; while it is unlikely in the short term that this scale will be replaced, the differences in slope across subscores of the ALSFRS-R should be acknowledged. Trials should be adequately powered such that the subscales of the ALSFRS-R can be analyzed individually (29). Moreover, as the ALSFRS-R does not include a cognitive domain, scales that assess cognition and behavioral aspects should also be incorporated into future trials (30), together with measures of quality of life. Clinical staging algorithms such as King's staging or MiToS staging, or neurophysiological testing, may help to identify responding subgroups and, ultimately, optimize the selection of compounds for confirmatory clinical trials (31,32). Given the differences between EMA and FDA guidelines, additional regulatory discussions may be warranted to align clinical trials across continents.

Innovative trial design

Background

The process of designing and initiating new clinical trials in ALS is a lengthy one. Currently, as new biotechnology companies enter the field, new trials are often designed from first principles rather than utilizing a previously established protocol. This leads to an unnecessary loss of resources and prior

knowledge, and results in wide variability in key design characteristics such as endpoints, study duration and sample size. These arbitrary design settings are likely to miss crucial treatment clues and further delay the development of effective treatment (33). Efficient, evidence-based trial methodology that harmonizes future clinical development paths is urgently required, using agreed master protocols with design input from academic researchers, industry and patient representation.

Considerations

Multi-arm, multi-stage (MAMS) and platform designs allow investigators to evaluate multiple treatments simultaneously. These study designs act as an overarching umbrella for multiple, individual sub-studies and harmonize efficacy outcomes, visiting schemes, procedures and infrastructures. This harmonization allows for large reductions in cost, duration, sample size and eliminates the need for repeated startup delays and protocol development when new compounds are discovered (34).

Future directions

The design of a master protocol requires extensive planning, multicentre collaboration and adaptations in trial methodology. Although we recognize that elements will need to be thoroughly discussed *a priori* (e.g. sharing of placebo arms and data-sharing) (35), these initiatives can significantly improve trial efficiency and may be of particular interest for smaller biotech companies as they provide low-cost access to existing infrastructures and patient populations.

The need for regulatory reform

Industry is open to fundamentally change drug development for ALS but requires amendments of the current regulatory guidelines to successfully implement innovation in their pipeline. Major future directions and regulatory themes are:

1. Relaxing the obligation of preclinical evidence using the *SOD1* mouse model, recognizing it is a model of mechanism, not disease, and promoting alternative human-derived models
2. Requiring the use of target-engagement biomarkers to improve preclinical-to-clinical translation
3. Implementing neurofilament testing in all stages of clinical development
4. Mediating the use of ALSFRS-R subscales, cognition, staging, advanced electrophysiology and digital health technology to enhance the detection of early efficacy
5. Training on outcome measures to ensure high quality data and minimize endpoint variability

6. Optimizing the adoption and implementation of prediction models in the design and analysis of clinical trials
7. Promoting the use of harmonized, innovative and adaptive clinical trial design to maximize efficiency
8. Advocating the adoption of unified electronic patient records and digital biomarker collection

Conclusion

There is an appetite for ongoing discussions of major topics in clinical trials between representatives from academia, patient advocacy groups, industry partners and fundraisers to consolidate our current approach toward drug development for ALS. Addressing these key topics will require further dynamic discussions with all stakeholders, and the EMA and FDA. Ultimately, real-world implementation in a large-scale collaboration such as TRICALS could significantly accelerate innovation in drug development for ALS and create a highway toward a cure.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Funding

This study was funded by the Dutch ALS foundation, UK Motor Neurone Disease Association (MND), ALS Liga Belgium and through the EU Joint Program – Neurodegenerative Disease Research, JPND. CJM is supported by the NIHR Sheffield Biomedical Research Center (BRC).

ORCID

Christopher J. McDermott  <http://orcid.org/0000-0002-1269-9053>

Philip Van Damme  <http://orcid.org/0000-0002-4010-2357>

Adriano Chio  <http://orcid.org/0000-0001-9579-5341>

Ammar Al-Chalabi  <http://orcid.org/0000-0002-4924-7712>

References

1. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347: 1425–31.
2. Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
3. Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J. The clinical trial landscape in amyotrophic lateral sclerosis-past, present, and future. Med Res Rev. 2020;40: 1352–33. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32043626>
4. Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13: 1127–38.
5. Van Den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology 2019;92:e1610–23.
6. McDermott CJ. Clinical trials in amyotrophic lateral sclerosis. Curr Opin Neurol. 2019;32:758–63.
7. Lutz C. Mouse models of ALS: Past, present and future. Brain Res. 2018;1693:1–10.
8. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008;9:4–15.
9. Chiò A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology 2020; 167:107986.
10. Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12: 435–42.
11. Kovalchuk MO, Heuberger J, Sleutjes B, Ziagkos D, van den Berg LH, Ferguson TA, et al. Acute effects of riluzole and retigabine on axonal excitability in patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled, crossover trial. Clin Pharmacol Ther. 2018;104:1136–45.
12. Ormel PR, Vieira de Sá R, van Bodegraven EJ, Karst H, Harschnitz O, Sneboer MAM, et al. Microglia innately develop within cerebral organoids. Nat Commun. 2018;9: 1–14.
13. Rutkove SB. Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12: 384–93.
14. Van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, Van Den Berg LH. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2018;89:156–61.
15. Neuwirth C, Braun N, Claeys KG, Bucelli R, Fournier C, Bromberg M, et al. Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: Real world experience from 27 centres. Clin Neurophysiol. 2018;129: 1756–62.
16. Shepheard SR, Wuu J, Cardoso M, Wiklundt L, Dinning PG, Chataway T, et al. Urinary p75ECD: a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology 2017;88:1137–43.
17. Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol 2019;10:1–7.
18. Gille B, De Schaepdryver M, Dedeene L, Goossens J, Claeys KG, Van Den Bosch L, et al. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?. J Neurol Neurosurg Psychiatry 2019;90:1338–46.

19. Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. *Stat Med*. 2006; 25:183–203.
20. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. *Biometrics* 1998;54:1014–29.
21. Chiò A, Canosa A, Gallo S, Cammarosano S, Moglia C, Fuda G, et al. ALS clinical trials: Do enrolled patients accurately represent the ALS population? *Neurology* 2011; 77:1432–7.
22. Van Eijk RPA, Westeneng HJ, Nikolakopoulos S, Verhagen IE, Van Es MA, Eijkemans MJC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. *Neurology* 2019;92:E451–60.
23. Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. *Lancet Neurol*. 2018; 17:423–33.
24. Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, et al. Being PRO-ACTive: what can a clinical trial database reveal about ALS? *Neurotherapeutics*. 2015; 12:417–23.
25. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf, 2016. Accessed February 23, 2020.
26. van Eijk RPA, Eijkemans MJC, Rizopoulos D, van den Berg LH, Nikolakopoulos S. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. *Clin Epidemiol*. 2018;10: 333–41.
27. van Eijk RPA, Bakers JNE, Bunte TM, de Fockert AJ, Eijkemans MJC, van den Berg LH. Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study. *J Neurol*. 2019;266:2387–95.
28. Garcia-Gancedo L, Kelly ML, Lavrov A, Parr J, Hart R, Marsden R, et al. Objectively monitoring amyotrophic lateral sclerosis patient symptoms during clinical trials with sensors: Observational study. *J Med Internet Res* 2019;21: 1–15.
29. Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry*. 2017;88:381–5.
30. Niven E, Newton J, Foley J, Colville S, Swingler R, Chandran S, et al. Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders. *Amyotroph Lateral Scler Frontotemporal Degener*. 2015;16:172–9.
31. Chiò A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry*. 2015;86:38–44.
32. Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. *Lancet Neurol*. 2018;17:416–22. Available from: [http://dx.doi.org/10.1016/S1474-4422\(18\)30054-1](http://dx.doi.org/10.1016/S1474-4422(18)30054-1)
33. Van Eijk RPA, Nikolakopoulos S, Roes KCB, Middelkoop BM, Ferguson TA, Shaw PJ, et al. Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. *J Neurol Neurosurg Psychiatry* 2019;90:1331–7.
34. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. *N Engl J Med*. 2017;377:62–70.
35. Collignon O, Gartner C, Haidich AB, James Hemmings R, Hofner B, Pétavy F, et al. Current statistical considerations and regulatory perspectives on the planning of confirmatory basket, umbrella, and platform trials. *Clin Pharmacol Ther* 2020;107:1059–67.